A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

NCT06791161 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Breast

Interventions

DRUG: Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences